TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19389746

Group type: EXPERIMENTAL
Intervention: Computerized visual perception rehabilitation programme with interactive patient-computer interface applying motion tracking technology
Number of subjects: 16

Group type: COMPARATOR
Intervention: PSS CogRehab program
Number of subjects: 16
Study: 17142065

Group type: EXPERIMENTAL
Intervention: Supervised Exercise Programme (SEP) for 3 months, 60 minutes, three times a week
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conservative Medical Therapy (CMT)
Number of subjects: 70
Study: 16009955

Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg/d
Number of subjects: 448

Group type: COMPARATOR
Intervention: Tamoxifen 20 mg/d
Number of subjects: 448
Study: 10989854

Group type: EXPERIMENTAL
Intervention: 4 microg/kg remifentanil and 3.5 mg/kg propofol
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0.4 mg/kg rocuronium
Number of subjects: 80
Study: 9192229

Group type: EXPERIMENTAL
Intervention: Education through monthly newsletters and semiannual classes on nutrition and exercise
Number of subjects: 1226

Group type: EXPERIMENTAL
Intervention: Education plus a lottery incentive for participation
Number of subjects: 1226

Group type: COMPARATOR
Intervention: No-contact control
Number of subjects: 1226
Study: 1311666

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium metered dose aerosol 4 mg twice daily
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 3923726

Group type: EXPERIMENTAL
Intervention: prazosin 20 mg/d orally (n = 12)
Number of subjects: 25

Group type: COMPARATOR
Intervention: placebo (n = 13)
Number of subjects: 25
Study: 30572270

Group type: EXPERIMENTAL
Intervention: Pea fiber (PF, 15 g/d in wafer form; n=29)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control (CO, isocaloric amount of wafers; n=24)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 53
Study: 30440874

Group type: EXPERIMENTAL
Intervention: Combined visual feedback with pelvic assistance force
Number of subjects: 15

Group type: COMPARATOR
Intervention: Visual feedback only
Number of subjects: 15
Study: 26875069

Group type: EXPERIMENTAL
Intervention: Risk rtPA mobile application
Number of subjects: 303
Study: 23392978

Group type: EXPERIMENTAL
Intervention: B-ultrasound-guided CHIPC
Number of subjects: 62

Group type: COMPARATOR
Intervention: Laparoscopy-assisted CHIPC
Number of subjects: 62
Study: 20939481

Group type: EXPERIMENTAL
Intervention: Manual reduction combined with uni-lateral PKP
Number of subjects: 85

Group type: COMPARATOR
Intervention: Simple uni-lateral PKP
Number of subjects: 85
Study: 18725895

Group type: EXPERIMENTAL
Intervention: Diet providing 13% of energy from sugars
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Diet providing 30% of energy from sugars
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Diet providing 50% of energy from sugars
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: All diets (13%, 30%, 50% sugar)
Number of subjects: 19

Group type: COMPARATOR
Intervention: BMI class (normal weight vs obese)
Number of subjects: 19
Study: 16632811

Group type: EXPERIMENTAL
Intervention: Acetaminophen 60 mg/kg rectally and 40 mg/kg orally
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ketoprofen 2 mg/kg IV twice
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination of acetaminophen and ketoprofen
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 120
Study: 14636810

Group type: EXPERIMENTAL
Intervention: Pathways Obesity Prevention Program (school-based physical activity intervention)
Number of subjects: 580

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 580
Study: 10780130

Group type: EXPERIMENTAL
Intervention: Universal preventive intervention for conduct disorder; specific dosage and duration not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified; details not available.
Number of subjects: 0
Study: 8737186

Group type: EXPERIMENTAL
Intervention: Dopamine infusion (0.01 microgram/kg/min)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg as i.v. bolus)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Dopamine infusion followed by metoclopramide (10 mg bolus after 2 hours)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Saline infusion (4-hour)
Number of subjects: 32
Study: 1419443

Group type: EXPERIMENTAL
Intervention: Propofol during CPB
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no propofol)
Number of subjects: 20
Study: 3100822

Group type: EXPERIMENTAL
Intervention: Visible haematuria screening in the morning
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Visible haematuria screening in the afternoon with terminal urine samples
Number of subjects: 418
Study: 29604894

Group type: EXPERIMENTAL
Intervention: Global ground-state potential energy surface (PES) for triplet O4 based on MS-CASPT2/maug-cc-pVTZ electronic structure calculations.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Many-body approach with accurate O-O pairwise interaction and fit to 10,180 electronic structure data points.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Geometries calculated for the fit include dissociative and vibrationally excited diatom-diatom collisions of O2.
Number of subjects: 0
Study: 29901362

Group type: EXPERIMENTAL
Intervention: Talcum powder
Number of subjects: 50

Group type: COMPARATOR
Intervention: Zinc oxide cream
Number of subjects: 50
Study: 24399554

Group type: EXPERIMENTAL
Intervention: Combination therapy (varenicline and bupropion SR)
Number of subjects: 506

Group type: COMPARATOR
Intervention: Varenicline monotherapy
Number of subjects: 506
Study: 23257348

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 20446998

Group type: EXPERIMENTAL
Intervention: Strength of Tobacco Control (SoTC)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Resources for tobacco control
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Population size, percent Caucasian, tobacco production, smoking prevalence
Number of subjects: 39
Study: 18343249

Group type: COMPARATOR
Intervention: CH-1504 (1, 5, 7.5, 10, 15, or 20 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: CH-1504 (7.5, 10, or 15 mg)
Number of subjects: 100
Study: 19135235

Group type: EXPERIMENTAL
Intervention: Probiotic mixture (2 lactobacilli, bifidobacteria, and propionibacteria)
Number of subjects: 1018

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1018

Group type: EXPERIMENTAL
Intervention: Probiotic mixture
Number of subjects: 1018
Study: 16005507

Group type: EXPERIMENTAL
Intervention: Eugenol-containing temporary cement (Temp bond) removed by excavator
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Eugenol-containing temporary cement (Temp bond) removed by sandblasting
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Eugenol-free temporary cement (Temp bond NE) removed by excavator
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Eugenol-free temporary cement (Temp bond NE) removed by sandblasting
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Total-etch bonding system (Excite/Variolink II)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Self-etching primer system (Panavia F 2.0)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group - fresh dentin scratched by excavator
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group - fresh dentin sandblasted
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group - fresh dentin with no surface treatment
Number of subjects: 140
Study: 11204899

Group type: EXPERIMENTAL
Intervention: Hidden speed cameras
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visible speed cameras
Number of subjects: 0
Study: 9030363

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) plus Lamivudine (3TC)
Number of subjects: 620

Group type: COMPARATOR
Intervention: Control treatments (other treatment arms)
Number of subjects: 620
Study: 7967434

Group type: EXPERIMENTAL
Intervention: Erwinia L-asparaginase therapy
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Prophylactic use of anticoagulants (under investigation)
Number of subjects: 21
Study: 3547386

Group type: EXPERIMENTAL
Intervention: Videotape version of the lesson
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Interactive video version of the lesson
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group (questionnaire only)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Experimental conditions (both videotape and interactive video)
Number of subjects: 162
Study: 11952670

Group type: EXPERIMENTAL
Intervention: Topical corticosteroid applied twice daily starting from day 4
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle applied twice daily starting from day 4
Number of subjects: 20
Study: 29660190

Group type: EXPERIMENTAL
Intervention: HBAI20 vaccine
Number of subjects: 34

Group type: COMPARATOR
Intervention: HBVaxPro©‐10 μg vaccine
Number of subjects: 34
Study: 27002062

Group type: EXPERIMENTAL
Intervention: Brivaracetam (150 mg single oral dose)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Rifampin (600 mg/day for 5 days)
Number of subjects: 26
Study: 24297971

Group type: EXPERIMENTAL
Intervention: Social networks intervention (peer support, monthly diabetes education sessions)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control group (standard diabetes education sessions)
Number of subjects: 138
Study: 22378892

Group type: EXPERIMENTAL
Intervention: Lower limb amputation (painless)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Tactile stimulation of the intact foot in amputees
Number of subjects: 18
Study: 20167142

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP), 88 micrograms, twice daily
Number of subjects: 1052

Group type: COMPARATOR
Intervention: Montelukast, 10 mg, daily
Number of subjects: 1052
Study: 18560254

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural treatment and cognitive strategy training (8 group sessions each)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 95
Study: 15958001

Group type: EXPERIMENTAL
Intervention: LigaSure
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional suture ligature
Number of subjects: 30
Study: 12463081

Group type: EXPERIMENTAL
Intervention: Insoluble iodine skin preparation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other skin preparation methods
Number of subjects: 0
Study: 10338233

Group type: EXPERIMENTAL
Intervention: Trousseau dilator
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tracheal hook
Number of subjects: 30

Group type: COMPARATOR
Intervention: Scalpel handle rotation
Number of subjects: 30
Study: 7796217

Group type: EXPERIMENTAL
Intervention: Four-session AIDS prevention program emphasizing risk education, sexual assertiveness, condom use, risk-related behavioral self-management, and problem-solving skills
Number of subjects: 52

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 52
Study: 1838750

Group type: EXPERIMENTAL
Intervention: Acitretin with PUVA
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo with PUVA
Number of subjects: 60
Study: 7025883

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2) vaginal pessaries (10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prostaglandin E2 (PGE2) vaginal pessaries (5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31014294

Group type: EXPERIMENTAL
Intervention: Manualised Body Psychotherapy (BPT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 24
Study: 28764579

Group type: EXPERIMENTAL
Intervention: Foley catheter balloon (FCB) insertion
Number of subjects: 300

Group type: COMPARATOR
Intervention: Intravaginal dinoprostone tablet placement
Number of subjects: 300
Study: 27142588

Group type: EXPERIMENTAL
Intervention: Targeted temperature management (TTM) at 33 ± 1 °C for 48 hours
Number of subjects: 350

Group type: COMPARATOR
Intervention: Targeted temperature management (TTM) at 33 ± 1 °C for 24 hours
Number of subjects: 350
Study: 25116294

Group type: EXPERIMENTAL
Intervention: ICU admission from hospital ward
Number of subjects: 1500

Group type: COMPARATOR
Intervention: ICU admission from emergency department
Number of subjects: 1500
Study: 22024956

Group type: EXPERIMENTAL
Intervention: Creative arts as a complementary therapy
Number of subjects: 0
Study: 20975465

Group type: EXPERIMENTAL
Intervention: Femoral nerve block
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham block
Number of subjects: 12
Study: 18407528

Group type: EXPERIMENTAL
Intervention: Rosehip powder
Number of subjects: 287

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study: 16084806

Group type: EXPERIMENTAL
Intervention: Isokinetic exercise and continuous ultrasound (US)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Isokinetic exercise and pulsed US
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Isokinetic muscular strengthening exercises
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no ultrasound)
Number of subjects: 120
Study: 15334868

Group type: EXPERIMENTAL
Intervention: Estrogens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electrostimulated acupuncture
Number of subjects: 0
Study: 10725579

Group type: EXPERIMENTAL
Intervention: Cetrorelix + recFSH
Number of subjects: 30

Group type: COMPARATOR
Intervention: HMG
Number of subjects: 30
Study: 8959592

Group type: EXPERIMENTAL
Intervention: Peer-planned social activities
Number of subjects: 20
Study: 1559177

Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 72

Group type: COMPARATOR
Intervention: Psychotherapy (Boys)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Psychotherapy (Girls)
Number of subjects: 72
Study: 2865859

Group type: EXPERIMENTAL
Intervention: famotidine 40 mg nocte
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: famotidine 20 mg bid
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: famotidine 40 mg bid
Number of subjects: 185

Group type: COMPARATOR
Intervention: ranitidine 150 mg bid
Number of subjects: 185
Study: 30913204

Group type: EXPERIMENTAL
Intervention: Moderate intensity treadmill exercise (MI)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Combined treadmill + resistance training (CT)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Nonexercise (NON-EX)
Number of subjects: 282
Study: 28675812

Group type: EXPERIMENTAL
Intervention: Dexamethasone, 8 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Diclofenac sodium, 50 mg associated with codeine, 50 mg
Number of subjects: 15
Study: 27447477

Group type: EXPERIMENTAL
Intervention: Oral diclofenac (50 mg) before and after ERCP
Number of subjects: 430

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Oral diclofenac (50 mg) in high-risk patients
Number of subjects: 430

Group type: COMPARATOR
Intervention: Placebo in high-risk patients
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Oral diclofenac (50 mg) in low-risk patients
Number of subjects: 430

Group type: COMPARATOR
Intervention: Placebo in low-risk patients
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Oral diclofenac (50 mg)
Number of subjects: 430
Study: 25468186

Group type: EXPERIMENTAL
Intervention: Brief CBT in addition to standard care
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 30
Study: 22668800

Group type: EXPERIMENTAL
Intervention: NT‐proBNP on admission
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Troponin T at discharge
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Discharge troponin T
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Admission NT‐proBNP
Number of subjects: 127
Study: 20923960

Group type: EXPERIMENTAL
Intervention: Low intravenous fat (32 g)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: High intravenous fat (64 g)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Low oral fat (32 g)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: High oral fat (64 g)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Intravenous saline
Number of subjects: 13
Study: 18351535

Group type: EXPERIMENTAL
Intervention: Microcoaxial phacoemulsification (MCP) with a 2.2 mm corneal incision width
Number of subjects: 109

Group type: COMPARATOR
Intervention: Standard phacoemulsification with a 3.0 mm incision width
Number of subjects: 109
Study: 15849296

Group type: EXPERIMENTAL
Intervention: Volleyball players (N=57)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Matched controls (N=55)
Number of subjects: 57
Study: 12428181

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ) supplementation (100 mg twice daily for 12 weeks)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Fenofibrate (200 mg each morning for 12 weeks)
Number of subjects: 74
Study: 9664865

Group type: EXPERIMENTAL
Intervention: Self-focus condition
Number of subjects: 60

Group type: COMPARATOR
Intervention: Other-focus condition
Number of subjects: 60

Group type: COMPARATOR
Intervention: Social-focus condition
Number of subjects: 60
Study: 7924476

Group type: EXPERIMENTAL
Intervention: Ozone (0.12 ppm)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Air (placebo)
Number of subjects: 15
Study: 2803605

Group type: EXPERIMENTAL
Intervention: Induction training
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Stress inoculation training
Number of subjects: 256

Group type: COMPARATOR
Intervention: No-contact control
Number of subjects: 256
Study: 1065467

Group type: EXPERIMENTAL
Intervention: Craniocervical irradiation and intrathecal methotrexate
Number of subjects: 117
Study: 29960005

Group type: EXPERIMENTAL
Intervention: dV‐Trainer
Number of subjects: 100

Group type: COMPARATOR
Intervention: No‐dV‐Trainer
Number of subjects: 100
Study: 27432113

Group type: EXPERIMENTAL
Intervention: Chain-loaded resistance (CLR) warm-up
Number of subjects: 16

Group type: COMPARATOR
Intervention: Free-weight resistance (FWR) warm-up
Number of subjects: 16
Study: 25074396

Group type: EXPERIMENTAL
Intervention: Contingency management
Number of subjects: 100

Group type: COMPARATOR
Intervention: Spirometric lung age
Number of subjects: 100

Group type: COMPARATOR
Intervention: Combined lung age and contingency management
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-contingency management
Number of subjects: 100
Study: 22498212

Group type: COMPARATOR
Intervention: Radiation alone
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Radiation plus androgen deprivation therapy
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Prostate specific antigen nadir increase
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Gleason 8 or greater
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Moderate/severe comorbidity
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Higher prostate specific antigen nadir
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 204
Study: 20012532

Group type: EXPERIMENTAL
Intervention: Force task (constant force against a rigid restraint)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Position task (maintain a constant elbow angle while supporting an inertial load)
Number of subjects: 20
Study: 18554075

Group type: EXPERIMENTAL
Intervention: Common/unique presentation approach
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Providing an overarching framework
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Less numerate consumers
Number of subjects: 303
Study: 15781825

Group type: EXPERIMENTAL
Intervention: Transcranial ultrasound (sonothrombolysis) for 1 hour
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 15
Study: 11803183

Group type: EXPERIMENTAL
Intervention: Clopidogrel (initial 300-mg loading dose, followed by 75-mg daily dose)
Number of subjects: 12500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12500
Study: 10788023

Group type: EXPERIMENTAL
Intervention: Nurse Practitioner
Number of subjects: 450
Study: 7621454

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: External radiation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deferred treatment
Number of subjects: 0
Study: 2199290

Group type: EXPERIMENTAL
Intervention: Colchicine (1 mg orally every morning)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (identical to colchicine)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 400861

Group type: EXPERIMENTAL
Intervention: 100 mg NA‐872 daily for 5 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 200 mg NA‐872 daily for 5 days
Number of subjects: 0
Study: 7119300

Group type: EXPERIMENTAL
Intervention: Prednisone liquid
Number of subjects: 12

Group type: COMPARATOR
Intervention: Prednisone tablet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Prednisolone sodium phosphate
Number of subjects: 12
Study: 29412001

Group type: EXPERIMENTAL
Intervention: 30 minutes of feedback training inspired by Implicit Person Theory (IPT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (untrained attending physicians)
Number of subjects: 0
Study: 30446595

Group type: EXPERIMENTAL
Intervention: Lasmiditan 200 mg
Number of subjects: 1856

Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg
Number of subjects: 1856

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1856
Study: 27073123

Group type: EXPERIMENTAL
Intervention: Same-day PPM implantation (Group A)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Delayed PPM implantation (Group B)
Number of subjects: 168
Study: 25137188

Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment over 12 weeks (8 sessions)
Number of subjects: 234
Study: 22512287

Group type: EXPERIMENTAL
Intervention: Telemedicine system with automated reminders
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (paper logbooks)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Telemedicine system
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80